Delaware Bans Private Equity Hospital Purchases in Push Against Healthcare Financialization

Delaware has enacted a first-in-the-nation, two-year moratorium on private equity firms acquiring nonprofit hospitals, drawing a hard line in the escalating battle over healthcare financialization. By signing Senate Bill 313 into law on Monday, Governor Matt Meyer temporarily blocked for-profit entities from purchasing acute care facilities or executing extractive sale-leaseback agreements through July 2028. The legislation operates on a clear premise: the private equity model of debt-loading and short-term wealth extraction is fundamentally incompatible with the long-term stability of community healthcare.[1][2]

The state's aggressive posture was forged by the catastrophic failure of a neighboring health system. Lawmakers watched as Prospect Medical Holdings, a private equity-backed firm, shuttered the Crozer Health network in nearby Pennsylvania, severely straining regional emergency services. Governor Meyer explicitly cited the Crozer collapse as the catalyst for the embargo, noting that private equity operators had "siphoned out hundreds of millions of dollars" while saddling the hospital with unsustainable debt. For Delaware, the moratorium is a preemptive strike to ensure that story does not cross state lines.[2][3]

But the legislative package extends far beyond ownership bans, fundamentally restructuring the financial relationship between hospitals and low-income patients. Senate Bill 13 establishes the most expansive statewide charity care standard in the United States. It mandates that all nonprofit hospitals provide completely free care to patients earning up to 300% of the Federal Poverty Level, effectively eliminating medical debt for a massive swath of the working class.[3][4]

Crucially, these financial assistance mandates are paired with automatic screening requirements. Patients will receive sliding-scale discounts—up to 400% of the poverty line—proactively, rather than being forced to navigate a complex bureaucratic maze while dealing with a medical crisis. Patient advocacy groups praised the provisions for standardizing community benefit requirements across all facilities, ensuring that nonprofit hospitals actually deliver the charitable value required to justify their tax-exempt status.[4]

The strongest counter-argument to Delaware's sweeping reforms came from the hospitals themselves, who warned that aggressive cost-control measures could backfire. The final pillar of the legislative trio, Senate Bill 1, tackles systemic spending by capping hospital prices and forcing investments into preventative medicine. It requires health insurers to direct at least 11.5% of their total medical spending toward primary care, shifting the financial model away from fee-for-service billing.[1][5]

However, the bill's original mechanism to cap hospital reimbursements at 250% of Medicare rates faced fierce industry pushback. The Delaware Healthcare Association warned that abrupt revenue reductions could force $413 million in service cuts and jeopardize 4,000 healthcare jobs, arguing that blunt price controls would starve safety-net facilities of the capital needed to operate. Acknowledging the economic fragility of the sector, lawmakers compromised: the Medicare-based caps will now be phased in gradually between 2029 and 2033, securing the hospital association's ultimate support.[1][3]

Delaware's legislative victory reflects a broader national trend of states stepping into the enforcement void left by federal gridlock. With the Trump administration signaling deep skepticism toward federal healthcare regulation, state legislatures have become the primary, and perhaps only, effective front for curbing corporate consolidation in medicine. Connecticut recently enacted a strict ban on hospital sale-leaseback transactions, while Massachusetts passed sweeping disclosure laws following the bankruptcy of the private equity-owned Steward Health Care system.[7]

Other states are utilizing different legal mechanisms to achieve the same defensive posture. Oregon recently passed the nation's strictest ban on corporate influence in medicine by closing loopholes in its 80-year-old "corporate practice of medicine" laws. California, Illinois, and Vermont have all advanced legislation this year aimed at blocking backdoor corporate control over clinical decisions and preventing investors from interfering with patient care.[7]

The two-year window created by Delaware's moratorium is explicitly designed to give the state legislature time to develop permanent statutory safeguards. As private equity firms continue to deploy hundreds of billions of dollars into the medical sector globally, state-level interventions like Delaware's are testing the legal limits of local regulatory power. By prioritizing patient stability over investor returns, Delaware has provided a tangible blueprint for how states can unilaterally dismantle the financialization of American healthcare.[1][2][7]